

1 **Publish or perish: reporting characteristics of peer-reviewed publications, pre-**
2 **prints and registered studies on the COVID-19 pandemic**

3

4 **Gianola S¹, Jesus TS², Barger S³, Castellini G^{1*}**

5

6

7 ¹IRCCS Istituto Ortopedico Galeazzi, Unit of Clinical Epidemiology, Milan, Italy

8

9 ²Global Health and Tropical Medicine (GHTM), WHO Collaborating Centre for Health Workforce
10 Policy and Planning, Institute of Hygiene and Tropical Medicine - NOVA University of Lisbon. Rua da
11 Junqueira 100, Lisbon 1349-008, Portugal.

12

13 ³Vita-Salute San Raffaele University, Milan, Italy

14

15

16 *greta.castellini@grupposandonato.it

17

18 **Abbreviation:** COVID-19, Coronavirus disease 19; SARS-COV-2, Severe Acute Respiratory Syndrome
19 coronavirus 2; PROSPERO, international prospective register of systematic reviews; MESH, Medical
20 Subject Headings; SRs, systematic reviews; RCTs, randomized controlled trials

21

22 **Abstract**

23 **Background**

24 The COVID-19 pandemic has resulted in a mass of academic papers being published in a very brief
25 span of time. Our aim was to compare the amount and reporting characteristics of COVID-19 related
26 peer-reviewed and pre-prints publications. We also investigated the amount of ongoing trials and
27 systematic reviews.

28 **Methods and findings**

29 A cross-sectional study of publications covering the COVID-19 pandemic time frame, up to May 20,
30 2020 was conducted. PubMed with appropriate combinations of Medical Subject Headings and
31 COVID-19 section of MedRxiv and BioRxiv archives were searched. We examined Clinicaltrial.gov,
32 Chinese Clinical Trial Registry, EU Register and 15 other trial registers as well as the international
33 prospective register of systematic reviews (PROSPERO). Characteristics of each publication source
34 were extracted. Regression analyses and Z tests were used to analyze publication trends over the weeks
35 and compare their relative proportions.

36 We found 3635 peer-reviewed publications and 3805 pre-prints, of which 8.6% (n=329) were
37 published in indexed journals. Peer-reviewed and pre-print publications amount both increased
38 significantly over time ($p<0.001$). Case reports (peer-reviewed: 6% vs pre-prints: 0.9%, $p<0.001$) and
39 letters (17.4% vs 0.5%, $p<0.001$) accounted for a greater share of the peer-reviewed compared to pre-
40 print publications. In turn, randomized controlled trials (0.22% vs 0.63% $p<0.001$) and systematic
41 reviews (0.08% vs 5%) accounted for a significantly greater share of the pre-print publications.
42 Clinicaltrials.gov, Chinese Clinical Trial Registry and EU register included 57.9%, 49.5 % and 98.9%
43 trials mostly still “recruiting”. PROSPERO amounted to 962 systematic review protocols.

44 **Conclusion**

45 Pre-prints were slightly more prevalent than peer-reviewed publications, yet both are growing. To fill
46 the void given by the absence of published primary studies, immediate opinions (i.e., letters) has
47 virulently been published in PubMed. However, preprints has been promoted as rapid responses to give
48 direct and promptly access at scientific findings in this pandemic.

49

50 **Keywords:** Pandemics; Coronavirus, COVID–19, SARS-CoV-2, Coronavirus Infections,
51 Transmission, Disease outbreaks, Prevention & control, Systematic Review, Randomized Controlled
52 Trial, Publications, Preprint.

53 **Introduction**

54 A novel human coronavirus named by the World Health Organization as Severe Acute Respiratory
55 Syndrome coronavirus 2 (SARS-COV-2) has been causing a pandemic of flu-like disease from the end
56 of 2019 (1). The global health emergency asked for urgent research priorities needed to inform the
57 public health response to the worldwide spread of 2019-nCoV infections (2). However, the enormity of
58 the scientific efforts and the speed at which the knowledge on this topic has been generated pose
59 significant difficulties for everyone to stay abreast of these developments (3). SARS-COV-2 has
60 sparked a parallel viral spread: science is being conducted, posted, and shared at an unprecedented rate.
61 A bibliometric and scientometric analysis of publications can quantitatively examine the research
62 progress of any topic and offer a comprehensive assessment of scientific research trends, which is
63 widely used for mapping knowledge in different scientific disciplines (4, 5). In an effort to address
64 challenges in Coronavirus Diseases 2019 (COVID-19) era and to better organize the emerging and
65 rapidly scientific developments, scoping reviews with a bibliometric and scientometric analyses have
66 been conducted (3, 6, 7) showing and visualizing the networks of contributing authors, institutions, and
67 countries. However, none of these reviews have focused on epidemiology and reporting characteristics
68 (8, 9) of this global burden assessing the evolution of research over the pandemic time (10-12). In the
69 COVID-19 burden, the scientific effort has been spread in different sources: registers of primary
70 studies (i.e, trials) and systematic reviews, preprints and peer-reviewed publications.
71 A clinical trials registry is a platform which catalogs registered clinical trials. Clinical trials can play an
72 important role in the COVID-19 to translate evidence of experimental and observational researches into
73 clinical practice (13, 14). Whereas, a systematic review protocol registry is an international database
74 which prospectively lists systematic reviews in health and social care. Systematic reviews should be
75 registered at inception (i.e. at the protocol stage) to help avoid outcome reporting biases, publication
76 bias, unplanned duplication and waste of resource, especially true in a period of global health
77 emergency (15, 16). Preprints are “preliminary reports of work that have not been certified by peer
78 review, at least yet. Hence, they should not be relied on to guide clinical practice or health-related

79 behavior and should not be reported in news media as established information” (17). Preprint servers
80 are open access online repositories housing preprint research articles that on one hand enable authors to
81 make their research immediately and freely available to receive commentary and peer review prior to
82 journal submission accelerating the dissemination of scientific findings (18). Preprints posted during
83 the Ebola and Zika outbreaks included novel analyses and new data, and most of those that were
84 matched to peer-reviewed publications were available more than 100 days before publication (18). On
85 the other hand, many pre-prints never become certified by peer review: indeed, less than 5% of Ebola
86 and Zika journal articles were posted as preprints prior to publication in journals (18). Therefore,
87 information in preprints lack the scrutiny and validity of an external, scientific review (19). In the
88 pandemic era, an analysis of preprints and ongoing researches (i.e., trials and reviews) can be important
89 since timeliness is key, even though peer reviews are expedited for new relevant research.

90

91 **Aims**

92 In the context above, we aim to provide a snapshot of the amount of scientific development on COVID-
93 19 worldwide, which may inform the current status of global research and provide insights on the needs
94 for future research in terms of its amount, design, publication venues, and reporting characteristics.
95 More specifically, we aim to do so by:

96 1) Comparing the amount of COVID-19 related research in peer-reviewed publications or pre-prints
97 (not peer-reviewed), including as stratified by key reported characteristics: species (ie. humans,
98 animals), study design (such as systematic reviews (SRs), randomized controlled trials (RCTs)) and
99 research area (such as drug treatment).

100 2) Inspect the amount and key reported characteristics of COVID-19 ongoing research in the registers
101 of clinical trials and systematic reviews (e.g., research Area).

102

103 **Methods**

104 Design: Cross-sectional study of publications and its key study and reporting characteristics COVID-19
105 related publications until May 20 2020.

106

107 **Data sources**

108 We searched for COVID-19 peer-reviewed publications in PubMed database through its indexation
109 system. PubMed is a comprehensive research database comprised of more than 30 million citations, as
110 of May 2020, for biomedical literature from MEDLINE, life science journals, and online books (20). In
111 the health field, there is evidence that adding databases other than PubMed only had modest impact on
112 SR results (21). In PubMed, Medical Subject Headings (MeSH) are organized in a hierarchical tree and
113 assigned to each paper by subject-specialist indexers. For COVID-19, we used the Supplementary
114 Concept Records (SCRs). MEDLINE indexers regularly come across substances in the literature that
115 are not currently MeSH headings. When this happens, the National Library of Medicine staff adds
116 these substances to the MeSH vocabulary as Supplementary Concept Records (SCRs). While MeSH
117 headings are updated annually, new SCRs are added weekly. Therefore, COVID-19 articles are
118 systemically indexed by research topic regardless of the specific words used by the authors. We
119 conducted target searches in PubMed that included the use appropriated combinations of MeSH terms
120 and SCRs (i.e. search filters) related to COVID-19 and related terms (e.g. SARS-COV-2, coronavirus
121 disease), filtered for specie, research designs, and research area (See **S1 Appendix. PubMed**
122 **database**).

123 We searched the two popular sources for COVID-19 related preprints, MedRxiv and BioRxiv
124 databases, proxy indicators of scientific not peer-reviewed literature. Papers are examined by in-house
125 staff who check for issues such as plagiarism and incompleteness (22) (see **S1 Appendix. Preprints**
126 **MedRxiv and BioRxiv database**).

127 We then investigated all primary registries that meet the requirements of the International Committee
128 of Medical Journal Editors (ICMJE) according to the WHO Registry Network. Primary registries in the
129 WHO Registry Network meet specific criteria for content, quality and validity, accessibility, unique
130 identification, technical capacity and administration (23). Additionally, we searched for International
131 prospective register of systematic reviews focusing on PROSPERO database (see **S1 Appendix.**
132 **Primary register; S1 Appendix. PROSPERO register**).

133 The whole searches in all sources were run in May 20, 2020 without restrictions on languages.

134

135 **Data extraction**

136 Data records obtained from PubMed, MedRxiv and BioRxiv, Trials registers and PROSPERO database
137 were imported to Excel for further grouping and analyses. Then the whole data extraction was
138 performed by one author and checked by the second author. Any uncertainties were discussed among
139 the data extractors.

140 For the peer-reviewed publications and pre-prints, we extracted the bibliometric data and then analyzed
141 and summarized the subsets focusing on the following study or reporting characteristics: specie (i.e.,
142 humans, animals), publication type (i.e., SRs, RCTs, Epidemiologic Studies, Letter), the distribution by
143 research area such as vaccine, treatment drug treatment, rehabilitation, diagnostic testing, measures for
144 infection prevention and control (i.e., social distance, masking), biology, according to the indexation
145 facilities and the respective search tags or filters. Since in the pre-prints no such filters/tags exists, we
146 manually extracted and coded the above topics. The study designs such as laboratory experiments (e.g.,
147 genomics), prognostic models were included in the epidemiology studies.

148

149 For the primary registers (e.g., trials), the following characteristics were filtered/tagged and extracted:
150 country, study type, phase, recruiting status. For data of PROSPERO database species and research
151 area/tag have been extracted.

152

153 **Data analysis**

154 Initially, descriptive statistics were used for the analysis. Over the volume of publications for each data
155 element (e.g. publication type), percentages and frequencies were computed and displayed in tabular
156 formats, paired between peer-reviewed and pre-print sources. After that, the amount of publications
157 over time (weekly) was plotted into a run chart. Then, simple linear regressions methods with the
158 ANOVA were used to analyze the growth of the number of COVID-19 publications over the weeks.
159 Finally, two-sample Z-tests, two tails, analyzed whether the proportion of each characteristics of peer-
160 reviewed source (i.e., PubMed) significantly differed from those of pre-print sources. P values <0.05
161 were considered significant. The data were stored and analyzed using STATA 16 software.

162

163 **Results**

164 We respond to each of our two specific study objectives in the respective subsections below.

165 **1) Amount and Characteristics of COVID-19 research peer vs not peer-reviewed (pre-print)** 166 **publications**

167 From December 2019 to May 2020, a total of 7440 COVID-19 related publications were found. From
168 these, 3635 (48.9%) were peer-reviewed, and 3805 (51.1%) were preprints. **Fig 1** reports the weekly
169 amount of both peer-reviewed and pre-print publications, from December 2019 to May 2020. The
170 increase of peer-reviewed and pre-print publications are both statistically significant over time (peer-
171 reviewed publications: $p < 0.001$ $r^2 = 0.8239$, and pre-prints: $p < 0.001$ $r^2 = 0.9133$, respectively). **Figs 2**
172 **and 3** shows the absolute and relative frequencies of peer-reviewed and pre-prints publications over
173 each week. **Fig 4** shows the trend of the ratio between relative frequencies of peer-reviewed and pre-

174 prints publications over weeks. The difference of the increase rate among relative frequencies between
175 the two groups was found not statistically significant over weeks ($p=0.2388$, $r^2=0.0856$).

176

177 [Fig.1]

178 **Figure 1. Linear regression over time for peer-reviewed and pre-print publications.**

179 [Fig.2]

180 **Figure 2. Absolute frequencies of peer-reviewed and pre-print publications over weeks.**

181 [Fig.3]

182 **Figure 3. Relative distribution of peer-reviewed and pre-print publications per week.**

183 [Fig.4]

184 **Figure 4. Linear regression of ratios between relative frequencies (peer-reviewed/pre-print
185 publications) over weeks.**

186

187 **Table 1** shows the reporting characteristics for both peer-reviewed and pre-prints COVID-19 related
188 publications. In both peer-reviewed publications and pre-prints, “human” subjects were predominant as
189 well as the most addressed research areas were prevention and control (26.1%, 950/3635 peer-reviewed
190 vs 42.4%, 1615/3805 pre-prints; $p<0.001$) and diagnosis (21.5%, 781/3635 peer-reviewed vs 25.3%,
191 962/3805 pre-prints; $p<0.001$).

192 Regarding the relative prevalence of study types, statistically significant differences were found among
193 peer-reviewed and pre-print publications. For instance, RCT designs were significantly more common
194 among pre-prints than among the peer-reviewed research (peer-reviewed: 0.2%; 8/3635 vs pre-prints:
195 0.6%, 24/3805; $P<0.001$). Similarly, SRs were significantly more common among preprints (peer-

196 reviewed: 0.8%, 29/3635 vs pre-prints: 5.0%, 193/3805; $P < 0.001$). Observational studies were also
197 significantly more common in pre-print research than peer-reviewed publications (peer-reviewed:
198 0.6%, 21/3635 vs pre-prints: 24.7%, 940/3805; $P < 0.001$). For case reports and letters, the picture was
199 reverse: these were significantly more common in peer-reviewed publications with a substantial
200 amount of letters to the editor (case reports, peer-reviewed: 6.0%, 219/3635 vs pre-prints: 0.9%,
201 35/3805; $P < 0.001$; letters, peer-reviewed: 17.4%, 632/3635 vs pre-prints: 0.5%, 19/3805; $P < 0.001$).
202 Overall, in both peer-reviewed publications and pre-prints the most addressed research areas were
203 prevention and control (26.1%, 950/3635 vs 42.4%, 1615/3805; $P < 0.001$) and diagnosis (21.5%,
204 781/3635 vs 25.3%, 962/3805).

205 Among pre-print publications, the 8.6% (329/3805) have been converted into peer-reviewed journals,
206 up to the covered dates, among which the two study designs most published were the observational
207 study (87.8%, $n=289/329$) and the RCT (5.6%, $n=18/329$) while the research areas of most interest
208 were prevention and control (40.7%, $n=134/329$) and diagnosis (31.6%, $n=104/329$).

209

210 **Table 1. Characteristics of COVID-19 peer-reviewed (PubMed) vs not peer-reviewed (Preprints)**
 211 **publications.**

Characteristics		PubMed (n=3635) n, %	Preprint (n=3805) n, %	Z value	% Difference	P value
Specie	Humans	3507 (96.5)	3634 (95.5)	2.14	1.0	0.033
	Animals	128 (3.5)	93 (2.4)	2.74	1.1	0.006
Publication type	Systematic Review and/or Meta-analysis	29 (0.8)	193 (5.0)	-10.83	-4.2	< 0.0001
	RCT	8 (0.2)	24 (0.6)	-2.71	-0.4	0.007
	<i>Phase I</i>	1	0	1.02	1.0	0.306
	<i>Phase II</i>	3	3	0.06	0.0	0.955
	<i>Phase III</i>	0	2	-1.38	-2.0	0.167
	<i>Phase IV</i>	0	3	-1.69	-3.0	0.090
	<i>Protocols</i>	0	4	-1.96	-4.0	0.051
	Epidemiologic Studies	222 (6.1)	3522 (92.6)	-74.55	-86.5	< 0.0001
	<i>Observational studies</i>	21 (0.6)	940 (24.7)	-31.02	-24.1	< 0.0001
	Case report	219 (6.0)	35 (0.9)	12.12	5.1	< 0.0001
	Letter	632 (17.4)	19 (0.5)	25.77	16.9	< 0.0001
Research Area/Tag	Vaccine	101 (2.8)	114 (2.9)	-0.56	-0.1	0.576
	Drug therapy	57 (1.6)	325 (8.5)	-13.62	-6.9	< 0.0001
	Diagnosis	781 (21.5)	962 (25.3)	-3.87	-3.8	< 0.0001
	Prevention and control (e.g., Masks, social distancing)	950 (26.1)	1615 (42.4)	-14.80	-16.3	< 0.0001
	Rehabilitation (e.g., Pulmonary rehabilitation)	23 (0.6)	5 (0.1)	3.53	0.5	< 0.0001
	Prognosis	123 (3.4)	844 (22.2)	-24.10	-18.8	< 0.0001
	Biology/Genetic	43 (1.1)	866 (22.8)	-28.41	-21.7	< 0.0001

212

213 *Note:* the sum of the characteristics does not respect the total number of publications since an
 214 overlapping among the specifications or other options can occur.

215

216 **2) Characteristics of COVID-19 ongoing research in the registers (trials and systematic**
 217 **reviews)**

218 **Table 2** shows that, in the Clinicaltrials.gov, 1621 of the 339863 records were focused on COVID-19
219 disease (0.5%). In turn, 652 of the 32553 records included in the Chinese Clinical Trial Registry
220 (ChiCTR), were focused on COVID-19 disease (2%). No other register had over 200 records of
221 COVID-19 research.

222 **Table 3** reported characteristics of the two primary registries with most volume of research COVID-19
223 related. The most investigated study type were the interventional studies in Clinicaltrials.gov as well as
224 in ChiCTR (respectively, 60% and 50%), with the phase 3 most reported in Clinicaltrials.gov (15%).
225 Regarding recruiting status, the most prevalent was “ongoing” across all registers (min-max: 47%-
226 99%).

227 **Table 4** provided reporting characteristics of PROSPERO database about the registered COVID-19
228 related systematic reviews. Almost all are focused on humans (99.7%) with the two most research areas
229 addressed to the treatments (19.1%) and health impacts (16.6%).

230

231

232 **Table 2. Primary Registries.**

	Publications	
	N° of Covid-19 related records (n,%)	N° total of records
Clinicaltrials.gov (USA)	1561(0.5)	339863
Chinese Clinical Trial Registry (ChiCTR)	648 (2.0)	32553
EU Clinical Trials Register (EU-CTR)	196 (0.5)	37185
Iranian Registry of Clinical Trials (IRCT)	195 (0.8)	24573
Clinical Trials Registry - India (CTRI)	99 (7.0)	1475
German Clinical Trials Register (DRKS)	67 (1.7)	3959
Japan Primary Registries Network (JPRN)	64 (0.2)	28794
Australian New Zealand Clinical Trials Registry (ANZCTR)	52 (0.2)	27187
The Netherlands National Trial Register (NTR)	52 (0.6)	8613
ISRCTN	35 (0.4)	11381
Brazilian Clinical Trials Registry (ReBec)	10 (0.2)	4085
Pan African Clinical Trial Registry (PACTR)	6 (0.5)	1162
Clinical Research Information Service (CRiS), Republic of Korea	2 (0.4)	505
Lebanese Clinical Trials Registry (LBCTR)	2 (3.0)	71
Peruvian Clinical Trial Registry (REPEC)	0 (0.0)	1849
Sri Lanka Clinical Trials Registry (SLCTR)	1 (0.3)	349
Thai Clinical Trials Registry (TCTR)	9 (3.0)	336
Cuban Public Registry of Clinical Trials(RPCEC)	19 (NA)	NA

233

234

235 **Table 3. Characteristics of Primary Registries with most volume of research COVID-19 related.**
 236 (Absolute frequencies). Na*: records not available due to not possible search

237

Characteristics		Clinicaltrials.gov (n total=1621) n, %	Chinese Clinical Trial Registry (ChiCTR) (n total=652) n, %	EU register (n total=196) n, %
Country	Africa	56 (3.5)	-	-
	Central America	3 (0.2)	-	-
	East Asia	120 (7.4)	-	-
	<i>Japan</i>	4 (0.2)	-	-
	Europe	628 (38.7)	-	196 (100.0)
	Middle east	83 (5.1)	-	-
	North America	380 (23.4)	-	-
	<i>Canada</i>	44 (2.7)	-	-
	<i>United States</i>	326 (20.1)	-	-
	<i>Mexico</i>	18 (1.1)	-	-
	North Asia	13 (0.8)	-	-
	Pacifica	10 (0.6)	-	-
	South America	48 (2.9)	-	-
	South Asia	20 (1.2)	-	-
	Study Type	East Asia	18 (1.1)	652 (100.0)
Interventional		940 (57.9)	323 (49.5)	-
Observational		663 (40.9)	260 (39.9)	-
Other (i.e.Patient Registries)		125 (7.7)	69 (10.6)	-
Phase	Early Phase 1	19 (1.2)	218* (33.4)	-
	Phase 1	91 (5.6)	13 (2.0)	6 (3.1)
	Phase 2	375 (23.1)	8** (1.2)	99 (50.5)
	Phase 3	241 (14.9)	3*** (0.5)	75 (38.3)
	Phase 4	55 (3.4)	67 (10.3)	33 (16.8)
	Not applicable	282 (17.4)	212 (32.5)	-
Recruiting status	Recruiting	795 (49.0)	308 (47.2)	194 (98.9)
	Complete	76 (4.7)	53 (8.1)	0
	Suspended/temporarily halted	7 (0.4)	16 (2.5)	0
	Other (e.g.. withdrawn)	8 (0.5)	275 (42.2)	1 (0.5)

238 Legend: Data were collected as reported from Primary registers.

239

240 * phase 0 for ChiCTR

241 **3 trials were I-II phase

242 ***1 trial was II-III phase

243

244

245 **Table 4. Characteristics of COVID-19 protocol of systematic reviews.**

Characteristics		N° Prospero registration (n=962)	
		N	%
Species	<i>Humans</i>	959	99.0
	<i>Animals</i>	3	0.3
Research Area/Tag as reported in PROSPERO	Chinese Medicine	70	7.0
	Diagnosis	52	5.0
	Epidemiological	155	16.0
	Genetics	7	0.7
	Health impacts	160	17.0
	Mental Health	76	8.0
	Other	31	3.0
	Personnel Protective Equipment	17	2.0
	Prognosis	50	5.0
	Public Health	10	1.0
	Transmission	26	3.0
	Treatments	184	19.0
	Vaccines	3	0.3

246

247 **Discussion**

248 The spread of COVID-19 has rapidly been matched by an impressive rise in related publications in
249 both peer-reviewed journals and pre-print servers (respectively, 3805 and 3635 records in about five
250 months, with both a significant statistically increase [$p < 0.001$]). However, it is critical for clinicians,
251 researchers and other stakeholders (e.g., government officers) to be able to identify, in a timely manner,
252 accurate, reliable and trustworthy research. The snapshot we obtained reveals the publication and study
253 register data on the first scientific endeavors to pandemic. To fill the void given by the absence of the
254 published primary studies, immediate opinions (i.e., letters, editorials and comments) has virulently
255 been published in the peer-reviewed literature, whereas empirical studies, including epidemiologic
256 aiming to discover the foundations for biologic, prognostic and prevention and controls research areas,
257 have been more commonly seen among pre-prints, up to May 20, 2020.

258 Our findings reflect a staged maturity of the research development. Even though the number of
259 recorded publications was found high and increasingly sharply in just a few months (not counting the
260 last few weeks likely due to indexation delays), we also found few higher-hierarchy evidence
261 publications like systematic reviews/meta-analysis ($n=29$) and randomized controlled trials ($n=8$) in
262 peer-reviewed journals. Others have found, similarly, a limited number of high-quality study designs
263 on the COVID-19 disease (14, 24, 25). There has been insufficient time to design, approve, execute,
264 and report such type of study designs; hence, it is probable that the percentage of these can rise over the
265 upcoming months. For instance, the numbers of trials protocols that were found registered as
266 “ongoing” in [clinicaltrials.gov](#) as well as in [ChiCTR](#) (respectively, $n=795$ and $n=308$) provide and
267 indicator of that upward trend. From both registers, we retrieved a total of 2273 trials: the growth of
268 this amount is remarkable since it has been reported on February 22, 2020, a total of 171 COVID-19-
269 related interventional trials (138 from [ChiCTR](#) and 33 from [ClinicalTrials.gov](#) (26) and on March 24,
270 2020, a total of 614 COVID-19-related interventional trials (471 from [ChiCTR](#) and 143 from
271 [ClinicalTrials.gov](#)) (27). This amount is justified by the breakthrough news from pandemic countries
272 (such as China) which drew significant attention to drug interventions (such as azithromycin,

273 hydroxychloroquine and antiviral drug)(28).

274 Besides, an important amount of systematic review protocols has been also registered in PROSPERO
275 (n=962), and mainly focused on research treatments. However, these reviews can be limited by the low
276 amount of clinical trials, or the lower quality of them (14). Indeed, secondary literature can be
277 supported by indirect evidence represented by primary studies involving different patients from those
278 of interest (i.e., COVID-19) as suggested by the Grading of Recommendations Assessment,
279 Development and Evaluation (GRADE) approach (29).

280 The clinical development process to find answers, treatments and vaccines for pandemics is stronger if
281 based on the highest levels of evidence such as systematic reviews and randomized controlled trials.
282 Companies and universities have been doing their best to accelerate experimental drugs and vaccines
283 for COVID-19 through their pipeline (30). The World Health Organization (WHO)'s Blueprint list
284 recognized coronaviruses as disease of priority importance: given the public health emergencies of
285 international concern and the absence of efficacious drugs and vaccines, coronaviruses disease are
286 considered to need accelerated research and development (31). For the duration of the Coronavirus
287 disease (COVID-19) outbreak several journals supported the immediate available publications through
288 preprints posted online (32-34). However, until the pre-print is not published in a notable peer-
289 reviewed journal it might get stuck in the limbo of credibility. We found only the 8% of pre-prints been
290 published as peer-reviewed publications: does the explanation for such low percentage rely on too little
291 time for conversion into a published version and a consequent delay of publication? Or is it merely a
292 waste of research? On one hand, the time it takes for a completed manuscript to be published
293 traditionally can be lengthy, up to 166 days for a preprint to be posted as DOI of a journal article (35).
294 Article publication delay, often due to constraints associated with the peer review process, can prevent
295 the timely dissemination of information in a global health emergency as COVID-19 pandemic (35). On
296 the other hand, studies that remain unpublished, research's "dark side of the moon", could represent a
297 waste of efforts and money annually invested in health and medical research globally (36, 37). It also
298 happens that important results in some areas (such as mathematics) have been published only on

299 preprint servers as ArXiv (38, 39). The potential harm from posting erroneous provisional research is
300 one reason why the medical community was so cautious about preprints in the first place (40).
301 However, to date, it is interesting to observe that pre-prints are actually gaining more attention and
302 citations than the corresponding peer-reviewed article (41). For the COVID-19 related articles, it is still
303 soon to analyze citation trends; yet, the publication trends here reviewed (i.e. up to May 20, 2020)
304 showed a higher amount of preprints than peer-reviewed publications and higher percentage of
305 empirical research among preprints. This contrasts with the findings from Lv et al up to February 6,
306 2020, such as those that articles in peer-reviewed journals accounted for 77.1% of the study
307 publications, pre-prints 14.1%, while 8% of the articles were merely posted online (42). Explanations
308 for these discrepancies can rely on the substantial amount of recent empirical studies that have been
309 more rapidly available in preprint serves and not in peer-reviewed forms, at least yet. A better fruition
310 of the trusted science can be enhanced by the better utilization of preprints. Preprints aim to give a
311 new, faster, and iterative alternative or complement to the current journal publication and peer review
312 system, proposing catalyze biomedical discovery, support career advancement, and improve scientific
313 communication (35). If all publishers endorsed preprint posting for research, this would become an
314 intrinsic preliminary step prior to the publication giving a clear signal to all scientists that preprints are
315 integral part to scientific communication (18). Tracking the pre-print into the publication process can
316 allow to control the reliability of research and distinct it from the final peer-reviewed publication. Also,
317 it might give benefit for both individual authors and the scientific community. The former can
318 immediately share their research and getting attention early, the latter can have direct access to the
319 most updated research, give feedback to improve manuscripts, arise discussion leading to new ideas,
320 follow-up studies, or collaborations with other research groups (43). This might be viewed as a
321 reinforcement and an essential step toward a more open and transparent peer review process which is
322 the cornerstone of our scientific activities and the full-proof system that ensures only quality research
323 papers released into the scientific community (19). Commentaries, letters to editors and other forms of
324 non-research publications were found essentially in peer-reviewed publication venues. These

325 publication types seem less prone for a preprint form, or on the contrary benefit highly from
326 certification by external peer-review in terms of not being essentially biased or personal perspectives.
327 In turn, on empirical research, informed readers can more objectively appraise the research methods,
328 the data presented, the validity of its conclusions, or limitations that are applicable, either in preprint or
329 peer-reviewed versions. To answer the pandemic needs, the best challenge in this emergency would be
330 increase the amount of completed and published research and translate it into practice.

331

332 **Limitations of the study**

333 This study only covers journals and publications indexed in PubMed: a comprehensive but not
334 exhaustive health research database. For pre-prints we used the COVID-19 section of these servers to
335 investigate the preprint versions at the time of our data extraction. Our data collection period was a
336 tightly defined window (December 2019-May 2020). However, since no filter nor topics are present for
337 selecting pre-prints categories and the average time taken to display search results is not always
338 optimal in the servers (44), a preferred hand screening was made. This partly threatens the validity of
339 the comparisons of study types between peer-reviewed and preprint publications. An illustrative
340 example may be that of the epidemiologic studies: in pre-prints, we recorded different study designs as
341 mentioned in the Methods section (such as Case-Control Studies, Cross-Sectional Studies but also
342 extending to biologic and mathematical models), whereas in PubMed we involved the regular MeSH
343 term that includes a clustered study designs (such as Case-Control Studies, Cross-Sectional Studies).
344 Besides, epidemiological studies are indexed in PubMed not as a “publication type” like RCTs; this can
345 affect the reliability, accuracy, and speed of the indexation of epidemiological studies in PubMed, e.g.
346 compared to pre-print servers. This may help explain why many studies in detected PubMed had no
347 classification for study type yet (i.e. the sum of the articles indexed for study types was clearly below
348 the total number of papers identified). Yet, clear-cut publication types like RCTs or letters to editors
349 may have had a faster a more reliable indexation. It could be reasonable to infer that many of the
350 studies without indexation for a publication or study type could be other than RCT or

351 commentaries/letters (e.g. epidemiologic, secondary data analysis, etc). Although indexation of
352 COVID-19 research has been prioritized, delays may apply and these may have been visible in the data
353 we obtained for the weeks of May, 2020.

354 When needed (i.e. when search filters or tags could not be reliably applied), manual coding was applied
355 by one researcher and verified by another rather than by two independent researchers. This is an option
356 typical of rapid review types, and a compromise needed to accelerate the results in an issue in which
357 the timeliness of the results is key and a certain degree of uncertainty on the precision of the results.
358 We did not adjusted characteristics for the country's population size, for example by using World
359 Bank's data in order to facilitate any comparison on the amount of studies per country
360 (<https://data.worldbank.org/>).

361

362 **Conclusion**

363 There is an unprecedented increase of publications amount on COVID-19 since the disease emerged.
364 There is a delay of accurate, reliable and trustworthy publication research. The vast majority of
365 scientific literature in the first five months of this epidemic outbreak is based on perspectives (e.g.
366 letters to the editor or commentaries) or reported (i.e. secondary) data rather than primary data. As
367 well, a large number of registered trials and systematic review with very few results were published so
368 far. The research focused on effective preventive/control and therapeutic strategies are still emerging
369 reflecting the initial response by the research community. For rapid responses, science should promote
370 preprints as a challenge and opportunity to give direct access to their research by submit them to
371 journals that accept preprints for their policies. However, at a time when journal editors and invited
372 reviewers are more solicited than ever, screening and reviewing preprints might benefit both the
373 authors and the scientific community and can provide the general public with timely access to scientific
374 discussion, helping to reinforce scientific credibility (33). Cautions should be taken regarding the
375 phenomenon of “publish or perish”: the efforts and time should be devoted to develop significant and

376 clinically relevant research agendas rather than investing more time to publish whatever researchers

377 can get into print.

378

379 **Author contributions**

380 Conceptualization: SG, GC, TJ;

381 Data curation, SG, GC;

382 Methodology: TJ, SG, GC;

383 Project Administration: SG, GC;

384 Formal analysis: GC, SG;

385 Investigation: SG, GC, SB;

386 Writing original draft: SG, GC;

387 Writing – Review & editing: SG, GC, TJ, SB.

388

389 **Data availability**

390 Data and code used in this study are available on OSF <https://osf.io/vby7x>

391


392 **References**

- 393 1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2
394 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *International*
395 *Journal of Antimicrobial Agents*. 2020;55(3):105924.
- 396 2. Cowling BJ, Leung GM. Epidemiological research priorities for public health control of the ongoing
397 global novel coronavirus (2019-nCoV) outbreak. *Euro surveillance: bulletin Europeen sur les maladies*
398 *transmissibles = European communicable disease bulletin*. 2020;25(6).
- 399 3. Haghani M, Bliemer MCI, Goerlandt F, Li J. The scientific literature on Coronaviruses, COVID-19 and
400 its associated safety-related research dimensions: A scientometric analysis and scoping review. *Safety Science*.
401 2020:104806.
- 402 4. Falagas ME, Papastamataki PA, Bliziotis IA. A bibliometric analysis of research productivity in
403 Parasitology by different world regions during a 9-year period (1995-2003). *BMC Infectious Diseases*.
404 2006;6:56.
- 405 5. Zyoud SH. Global research trends of Middle East respiratory syndrome coronavirus: a bibliometric
406 analysis. *BMC Infectious Diseases*. 2016;16:255.
- 407 6. Bonilla-Aldana DK, Quintero-Rada K, Montoya-Posada JP, Ramirez-Ocampo S, Paniz-Mondolfi A,
408 Rabaan AA, et al. SARS-CoV, MERS-CoV and now the 2019-novel CoV: Have we investigated enough about
409 coronaviruses? - A bibliometric analysis. *Travel Medicine and Infectious Disease*. 2020;33:101566.
- 410 7. Hossain MM. Current Status of Global Research on Novel Coronavirus Disease (COVID-19): A
411 Bibliometric Analysis and Knowledge Mapping. Available at SSRN: <https://ssrn.com/abstract=3547824> or
412 <http://dxdoiorg/102139/ssrn3547824> 2020.
- 413 8. Gianola S, Gasparini M, Agostini M, Castellini G, Corbetta D, Gozzer P, et al. Survey of the reporting
414 characteristics of systematic reviews in rehabilitation. *Physical Therapy*. 2013;93(11):1456-66.
- 415 9. Page MJ, Shamseer L, Altman DG, Tetzlaff J, Sampson M, Tricco AC, et al. Epidemiology and
416 Reporting Characteristics of Systematic Reviews of Biomedical Research: A Cross-Sectional Study. *PLoS*
417 *medicine*. 2016;13(5):e1002028.
- 418 10. Grant C, Williams B, Driscoll T. Historical trends in publications in the *International Journal of*
419 *Epidemiology*. *International Journal of Epidemiology*. 2018;47(3):938-41.

- 420 11. Lin RT, Soeberg MJ, Chien LC, Fisher S, Takala J, Lemen R, et al. Bibliometric analysis of gaps in
421 research on asbestos-related diseases: declining emphasis on public health over 26 years. *BMJ open*.
422 2018;8(7):e022806.
- 423 12. Muthuvel T, Isaakidis P, Shewade HD, Kattuppara L, Singh R, Govindarajulu S. Leprosy trends at a
424 tertiary care hospital in Mumbai, India, from 2008 to 2015. *Global Health Action*. 2016;9:32962.
- 425 13. Ligthelm RJ, Borzi V, Gumprecht J, Kawamori R, Wenying Y, Valensi P. Importance of observational
426 studies in clinical practice. *Clinical Therapeutics*. 2007;29(6 Pt 1):1284-92.
- 427 14. Alexander PE, Debono VB, Mammen MJ, Iorio A, Aryal K, Deng D, et al. COVID-19 coronavirus
428 research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine.
429 *Journal of Clinical Epidemiology*. 2020.
- 430 15. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for
431 systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews*. 2015;4:1.
- 432 16. Booth A, Clarke M, Ghersi D, Moher D, Petticrew M, Stewart L. An international registry of systematic-
433 review protocols. *Lancet*. 2011;377(9760):108-9.
- 434 17. MedRxiv. <https://www.medrxiv.org/>. Accessed on June 4 2020.
- 435 18. Johansson MA, Reich NG, Meyers LA, Lipsitch M. Preprints: An underutilized mechanism to accelerate
436 outbreak science. *PLoS Medicine*. 2018;15(4):e1002549.
- 437 19. Kelly J, Sadeghieh T, Adeli K. Peer Review in Scientific Publications: Benefits, Critiques, & A Survival
438 Guide. *EJIFCC*. 2014;25(3):227-43.
- 439 20. Database PTWsmCB. <https://library.sacredheart.edu/c.php?g=29690>. Accessed on June 4 2020.
- 440 21. Halladay CW TT, Schmid IT, Schmid CH, Dahabreh IJ. Using data sources beyond PubMed has a
441 modest impact on the results of systematic reviews of therapeutic interventions. *Journal of Clinical*
442 *Epidemiology*. 2015:1076-84.
- 443 22. Kwon D. How swamped preprint servers are blocking bad coronavirus research. *Nature* 2020;Vol 581
- 444 23. Registers WHO. <https://www.who.int/ictrp/network/primary/en/>. Accessed on June 4 2020.
- 445 24. Kambhampati SBS, Vaishya R, Vaish A. Unprecedented surge in publications related to COVID-19 in
446 the first three months of pandemic: A bibliometric analytic report. *Journal of Clinical Orthopaedics and Trauma*.
447 2020.

- 448 25. Gori D, Boetto E, Fantini M. The early scientific literature response to the novel Coronavirus outbreak:
449 who published what? doi: <https://doi.org/10.1101/2020032520043315>. 2020. Pre-print on MedRxiv.
- 450 26. Yang Z, Yongyue W, Sipeng S, Mingzhi Z, Feng C. Appealing for Efficient, Well Organized Clinical
451 Trials on COVID-19. doi:<https://doi.org/10.1101/2020030520031476>. 2020. Pre-print on MedRxiv.
- 452 27. Luo Q, Qin T. Managing clinical trials for covid-19: the importance of ethics committees. *BMJ*.
453 2020;369:m1369.
- 454 28. Khachfe H, Akl E. A large number of COVID-19 interventional clinical trials were registered soon after
455 the pandemic onset: a descriptive analysis, *Journal of Clinical Epidemiology*,
456 doi:<https://doi.org/10.1016/j.jclinepi.2020.06.005>. 2020.
- 457 29. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8.
458 Rating the quality of evidence--indirectness. *Journal of clinical epidemiology*. 2011;64(12):1303-10.
- 459 30. Hodgson J. The pandemic pipeline. *Nature biotechnology*. 2020;38(5):523-32.
- 460 31. Organization WHO. List of Blueprint priority diseases URL: [https://www.who.int/activities/prioritizing-](https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts)
461 [diseases-for-research-and-development-in-emergency-contexts](https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts); 2018.
- 462 32. Graham F. Daily briefing: medRxiv brings preprints to medical science. *Nature Briefing*. 2019.
- 463 33. Vabret N, Samstein R, Fernandez N, Merad M, Sinai Immunology Review P, Trainees, et al. Advancing
464 scientific knowledge in times of pandemics. *Nature reviews Immunology*. 2020;20(6):338.
- 465 34. Wpro. Coronavirus disease (COVID-19) Call for Papers. *Western Pacific Surveillance and*
466 *Response*.<https://ojs.wpro.who.int/ojs/index.php/wpsar>. Accessed on June 4 2020.
- 467 35. Iwema CL, LaDue J, Zack A, Chattopadhyay A. search.bioPreprint: a discovery tool for cutting edge,
468 preprint biomedical research articles. *F1000Research*. 2016;5:1396.
- 469 36. Glasziou P, Chalmers I. Comment: Can it really be true that 50% of research is unpublished? Accessed
470 on June 4 2020. 2017;[https://blogs.bmj.com/bmj/2017/06/05/paul-glasziou-and-iain-chalmers-can-it-really-be-](https://blogs.bmj.com/bmj/2017/06/05/paul-glasziou-and-iain-chalmers-can-it-really-be-true-that-50-of-research-is-unpublished/)
471 [true-that-50-of-research-is-unpublished/](https://blogs.bmj.com/bmj/2017/06/05/paul-glasziou-and-iain-chalmers-can-it-really-be-true-that-50-of-research-is-unpublished/).
- 472 37. Waste LssioR. <https://www.thelancet.com/series/research>. Accessed on June 4 2020.
- 473 38. <https://en.wikipedia.org/wiki/Preprint>. Accessed on June 4 2020.

- 474 39. Lariviere V, Sugimoto CR, Macaluso B, Milojevic S, Cronin B, Thelwall M. arXiv e-prints and the
475 journal of record: An analysis of roles and relationships. DOI:10.1002/asi.23044. Accessed on June 4 2020.
476 2020.
- 477 40. All that's fit to preprint. Nature Biotechnology. 2020;38(5):507. doi: 10.1038/s41587-020-0536-x.
- 478 41. Fu DY, Hughey JJ. Releasing a preprint is associated with more attention and citations for the peer-
479 reviewed article. eLife. 2019;8.
- 480 42. Lv M, Luo X, Estill J, Liu Y, Ren M, Wang J, et al. Coronavirus disease (COVID-19): a scoping review.
481 Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
482 2020;25(15).
- 483 43. Plos. <https://plos.org/open-science/preprints>. Accessed on June 4 2020.
- 484 44. f1000research.com. search.bioPreprint: a discovery tool for cutting edge, preprint biomedical research
485 articles [version 2; peer review: 2 approved]. <https://f1000researchcom/articles/5-1396/v2>. Accessed on June 12
486 2020.
- 487



■ Peer reviewed publications (PubMed) ■ Preprints

